Africa, Agriculture, Food & Nutrition, People, Health

Making a difference: Novartis releases 2017 Corporate Responsibility Report

Novartis | Feb 01, 2018

SHARE

The United Nations Sustainable Development Goals (SDGs) brought in a new era of global development objectives to tackle the world’s most pressing problems, and the active participation of business is a principle driver in achieving these goals. Ending poverty, protecting the environment and ensuring prosperity for all needs full co-operation from both the public and private sectors. Best practices for corporate reporting on the SDGs still need to be established to address these challenges. This will empower corporate action that can make the achievements of the SDGs a reality.

Novartis is one of the world’s leading pharmaceutical companies, with 123,000 employees, products in more than 180 countries and a reach of 1 billion patients globally. As a leader in pharma, Novartis is known for strong performance in the Access to Medicine Index, based on a forward-looking access to healthcare strategy and a strong pipeline of innovative medicines in key therapeutic areas. 

For the fifth consecutive year, Novartis is publishing an annual Corporate Responsibility (CR) Report. Building on the company’s long history of corporate responsibility, the report is divided into four chapters based on CR material clusters: access to healthcare, innovation, patient health and safety and ethical business practices. The company was also ranked No. 4 on Fortune Magazine’s “Change the World” list, which recognized companies that have a positive social impact through activities that are part of their core business strategy. 

Highlights of Novartis achievements in 2017 include:

  • Provided medicine to approximately 46 million patients through access programs, as well as health education, infrastructure development and other programs to another 15 million people worldwide
  • Delivered more than 800 000 Novartis Access treatments for chronic diseases to Kenya, Lebanon, Ethiopia and Cameroon since program launch in 2015, each providing one-month supply of medicine
  • Delivered 850 million malaria treatments, including 350 million pediatric treatments, without profit to malaria-endemic countries since 2001

Download the full report here.

Reports

NESTLE

Your subscription has now been confirmed. We look forward to keeping you up to date on the latest news around sustainable development in your chosen fields.

www.nestle.com